Ann: Director Appointment, page-43

Let's not miss a (possibly the) major implication with this appointment.

Most comment is about what Lyn Cobley brings to MSB. Quite appropriate. But reflect on what she thinks. Ms Cobley is already a highly respected figure in Australian commercial circles. Which extends to major international areas. Remuneration is secondary to her motivation to accept an offer of board membership. She would have done colossal diligence, able to call upon the highest expertise and critical opinion about MSB, before risking her hard-won reputation on accepting this role. She has nowhere to go except up, unless she risks all that on a doubtful choice. She sees an opportunity for connection with and contributing to a major advance in human health. This is more than money to her. She must have confidence in MSB's management and future.

Lyn Cobley obviously has no doubt about MSB's board, governance, ethics, financial sustainability. She checked all that out before putting her reputation and self regard on the line. Us LTSH are well satisfied about the science. So is the FDA, referring to Ryoncil's approval.

Nothing else is required for total confidence. Everybody, relax. The only undetermined factor is time, and that is shrinking. "Short order" will soon refer to yesterday